SOUTH SAN FRANCISCO, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Exelixis, Inc. and Bristol-Myers Squibb Company will announce today a worldwide collaboration to discover, develop and commercialize novel targeted therapies for the treatment of cancer.
The discussion of the new collaboration by Exelixis management will be webcast at 5:00 a.m. PT/8:00 a.m. ET and may be accessed in the Event Calendar page under Investors at www.exelixis.com .
An archive of this discussion will be available until 9:00 p.m. PT /12:00 a.m. ET on January 18, 2007. Access numbers for this replay are: 1-877-660-6853 (domestic) and 1-201-612-7415 (international); Account number is 286; Conference ID number is: 224272.
About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company's web site at www.exelixis.com
Exelixis, Inc.CONTACT: investors, Charles Butler, Director, Corporate Communications,+1-650-837-7277, or cbutler@exelixis.com, or media, Soleil MaxwellHarrison, Senior Manager, Corporate Communications, +1-650-837-7012, orsharrison@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com/
